CCS
PBYI icon

Crosspoint Capital Strategies’s Puma Biotechnology PBYI Stock Holding History

Crosspoint Capital Strategies’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-35,349
Closed -$3.49M – 63
2017
Q4 		$3.49M Sell
35,349
-439
-1% -$49.1K 2.89% 24
2017
Q3 		$4.29M Buy
+35,788
New +$3.33M 3.32% 3

Other funds holding PBYI

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Crosspoint Capital Strategies's PBYI Position: Q1 2018 in Review

Crosspoint Capital Strategies sold out of Puma Biotechnology (PBYI) in Q1 2018, closing a stake of 35,349 shares — an estimated $3.49M sold.

Crosspoint Capital Strategies first reported a position in PBYI in Q3 2017 and held it in 2 quarters. The position peaked at $4.29M in Q3 2017. 178 funds tracked by Wall St. Rank hold PBYI as of Q1 2018.

  • Crosspoint Capital Strategies reported no remaining Puma Biotechnology position as of Q1 2018 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 35,349 Puma Biotechnology shares in Q1 2018, an estimated $3.49M.
  • Crosspoint Capital Strategies first reported a position in Puma Biotechnology in Q3 2017 and held it in 2 quarters.
  • Crosspoint Capital Strategies's Puma Biotechnology position peaked at $4.29M in Q3 2017.
  • 178 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2018.

Based on Crosspoint Capital Strategies's 13F filing for Q1 2018, filed 14 May 2018.